Beclometasone / Formoterol / Glycopyrronium: 5 agencies, 2017–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused beclometasone / formoterol / glycopyrronium: all 7 decisive outcomes across 3 agencies were positive or positive with restrictions.
Assessment has run over 7.8 years, from 20 Jul 2017 at AWMSG (Wales) to 16 May 2025 at AOTMIT (Poland).
AOTMIT (Poland) changed its position: recommended on 4 Oct 2018, restricted by 16 May 2025.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), SMC (Scotland) and PHARMAC (New Zealand) among them — hold no record for beclometasone / formoterol / glycopyrronium at all.
The file is active: 3 of 13 records date from 2023 or later.
4 distinct indication wordings are recorded for beclometasone / formoterol / glycopyrronium by the agencies that label one in English (AWMSG and PBAC).
1 of these 13 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess beclometasone / formoterol / glycopyrronium, on 20 Jul 2017; HIRA (South Korea) did not open a file until 12 Oct 2023 — a wide spread of 6.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 4 of 7 decisive outcomes narrowed beclometasone / formoterol / glycopyrronium to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland) and HIRA (South Korea).
3 of the 5 agencies here assessed beclometasone / formoterol / glycopyrronium more than once, AWMSG (Wales) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed beclometasone / formoterol / glycopyrronium.
The full ledger for beclometasone / formoterol / glycopyrronium reads 5 not assessed, 4 restricted, 3 recommended and 1 deferred.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 16 May 2025 | Trimbow reimbursement recommendation | recommended conditionally | source |
| HIRA (South Korea) | 12 Oct 2023 | 1. 성인 천식의 유지요법 2. 성인 중증의 만성 폐쇄성폐질환 (COPD) 의 유지요법 | reimbursable only at the evaluated price | source |
| PBAC (Australia) | 2022 | Asthma | Deferred | source |
| TLV (Sweden) | 12 Jul 2021 | Trimbow inhalationspulver ingår i högkostnadsskyddet | general subsidy | source |
| AWMSG (Wales) | 21 May 2021 | Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting bet… | outside AWMSG criteria | source |
8 further decisions for beclometasone / formoterol / glycopyrronium, across 3 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- budesonide / formoterol / glycopyrronium — divergent outcome (not assessed vs recommended) on a shared indication
- budesonide — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- mesalazine — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- prednisolone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
Coverage: 13 decisions for beclometasone / formoterol / glycopyrronium from 5 agencies, 2017 to 2025. Data to 7 Sep 2026. ATC class A07E — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.